Impax Settles IP Row With J&J Over Generic Concerta
Impax Laboratories Inc. on Friday inked a deal with two Johnson & Johnson subsidiaries, giving Impax licensing rights to produce generic versions of the attention deficit hyperactivity disorder drug Concerta and...To view the full article, register now.
Already a subscriber? Click here to view full article